Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Multicenter, Randomized, Comparative, Open-label, Phase 3 Study to Assess the Immunogenicity and Safety of DTaP-IPV (Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus) Vaccine Administered to Healthy Infants

NCT02458183 is registered in ClinicalTrials.gov with Boryung Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT02458183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02458183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Multicenter, Randomized, Comparative, Open-label, Phase 3 Study to Assess the Immunogenicity and Safety of DTaP-IPV (Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus) Vaccine Administered to Healthy Infants
Lead sponsor
Boryung Pharmaceutical Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
February 2, 2015
Completion date
May 5, 2018
Enrollment
476 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, pertussis, poliomyelitis, tetanus